Participatory Genomic Testing Can Effectively Disseminate Cardiovascular Pharmacogenomics Concepts within Federally Qualified Health Centers: A Feasibility Study

Abstract

Objective: We assessed feasibility of an educational program designed to enhance stakeholder knowledge and perceptions of pharmacogenomics at a federally qualified health center (FQHC).Design: FQHCs have a rich history of providing care to the underserved, but often are not represented by studies evaluating cutting-edge concepts. We used a novel educational platform to provide participato­ry genomic testing and classroom education. We assessed participant knowledge and perceptions using questionnaires between May and July 2018.Setting: We partnered with a FQHC affili­ated with an academic medical center in Chicago. Participants: Using convenience sampling, we recruited 20 providers and 10 commu­nity members for a feasibility study. Provid­ers included physicians, physician extend­ers, community health workers, and patient health navigators. Community members were patients, supporters, and/or FQHC advisory board members.Intervention: Participants had the option to undergo personal genomic testing. Online educational modules included basic genet­ics, cardiovascular pharmacogenomics, and personalized medicine. Education conclud­ed in a 2-hour live course with case-based discussions.Main Outcome Measures: Our main out­come was testing pilot feasibility. Baseline knowledge and perceptions were compared with post-intervention assessments using descriptive statistics, t tests (or Wilcoxon rank-sum) for continuous variables and chi-squared (or Fisher’s exact) for categorical variables.Results: We found that attitudes toward the intervention were positive and remained so after intervention. Our intervention was both feasible and acceptable. Genomics knowledge increased for nearly all partici­pants.Conclusions: We have determined that a pharmacogenomics educational program tailored for an underrepresented commu­nity is feasible and acceptable. Outcomes will advise methodology for larger imple­mentation studies. Ethn Dis. 2020;30(Suppl 1):167-176; doi:10.18865/ed.30.S1.167

A Scoping Review of Attitudes and Experiences with Pharmacogenomic Testing among Patients and the General Public: Implications for Patient Counseling

“…Of these, 35 met eligibility criteria and were included in the analysis. An additional two articles were identified upon reference review of eligible articles and also included in the analysis, for a final total of 37 articles [ 1 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ]. Figure 1 summarizes the identification and selection process for inclusion.…”